UnknownNot Applicable

Clinical-immunological Features of Anti-NMDAR Encephalitis

France400 participantsStarted 2022-02-01

Plain-language summary

Using a retrospective cohort of 501 patients with anti-NMDAR encephalitis to assess clinical and immunological prognostic biomarkers

Who can participate

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient with neurological disorder * Patient with NMDAR antibodies in sera or CSF Exclusion Criteria: * \- No available clinical data * Patient without NMDAR antibodies or neurological disorder

What they're measuring

Modified Rankin scale (mRS)

Timeframe: Baseline

Trial details

NCT IDNCT05738668

SponsorHospices Civils de Lyon

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-10-01

View on ClinicalTrials.gov More Anti NMDA Receptor Encephalitis trials